• Clinical trial collaboration agreement leverages NEC’s cutting-edge AI technology and VAXIMM’s novel oral T-cell immunotherapy technology
• NEC to make an equity investment in VAXIMM
TOKYO & BASEL, Switzerland & MANNHEIM, Germany-Thursday 14 November 2019 [ AETOS Wire ]
For more information, please visit https://www.nec.com/en/global/solutions/ai-drug/
NEC’s neoantigen prediction utilizes its proprietary AI which is combined with NEC OncoImmunity AS’s bioinformatics pipelines – making it the leading neoantigen prediction system in the field. NEC comprehensively evaluates candidate neoantigens, which allows it to effectively prioritize numerous candidate neoantigens identified in a single patient.
(BUSINESS WIRE)
-- NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network
technologies, and VAXIMM AG, a Swiss/German biotech company focused on
developing oral T-cell immunotherapies, today announced that the
companies have signed a strategic clinical trial collaboration agreement
and an equity investment agreement to develop novel personalized
neoantigen cancer vaccines.
Under the
terms of the collaboration agreement, which is non-exclusive to both
parties, NEC will provide funding for a Phase I clinical trial. NEC and
VAXIMM will co-develop personalized cancer vaccines using NEC’s
cutting-edge artificial intelligence (AI) technology, which is utilized
in its Neoantigen Prediction System, and VAXIMM’s proprietary T-cell
immunotherapy technology. The vaccines are planned to be evaluated in a
Phase I clinical trial in various solid tumors. VAXIMM will be
responsible for conducting the clinical trial, which is expected to be
initiated in 2020.
NEC has the
option for development and commercialization rights to the program
worldwide, except for China and other Asian territories outside of
Japan.
Osamu
Fujikawa, Senior Vice President, NEC Corporation, said: “Cancer is
consistently one of the most serious healthcare challenges, with
millions of new cases diagnosed worldwide annually. NEC’s core
technology is well positioned for the development of personalized
medicine, and we are strongly committed to delivering effective
treatments for cancer patients. We are delighted to be working with
VAXIMM in order to develop an optimal immunotherapy for each individual
patient.”
Heinz
Lubenau, PhD, Chief Operating Officer and Co-Founder of VAXIMM, said:
“We are excited to enter this alliance with NEC and to have their strong
support of VAXIMM. NEC’s novel AI technology will enable not only the
identification but also the prioritization of neoantigens from each
patient, facilitating the optimal potential treatment for each
individual. Once the list of neoantigens is available, we will be able
to apply our technology to quickly produce a personalized vaccine.
Individualized therapy is at the cutting edge of cancer treatment today,
and, with this collaboration, we are able to further contribute to this
approach.”
Notes:
About NEC’s AI Drug Development Business
For more information, please visit https://www.nec.com/en/global/solutions/ai-drug/
About NEC's Neoantigen Prediction System
NEC’s neoantigen prediction utilizes its proprietary AI which is combined with NEC OncoImmunity AS’s bioinformatics pipelines – making it the leading neoantigen prediction system in the field. NEC comprehensively evaluates candidate neoantigens, which allows it to effectively prioritize numerous candidate neoantigens identified in a single patient.
Press release:
NEC acquires Norwegian bioinformatics company, OncoImmunity AS
https://www.nec.com/en/press/201907/global_20190729_01.html
NEC acquires Norwegian bioinformatics company, OncoImmunity AS
https://www.nec.com/en/press/201907/global_20190729_01.html
About NEC Corporation
For more information, visit NEC at http://www.nec.com.
For more information, visit NEC at http://www.nec.com.
About VAXIMM
For more information, please see www.vaximm.com.
For more information, please see www.vaximm.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191111005716/en/
Contacts
Media Inquiries
NEC Corporation
Joseph Jasper
Phone: +81 3 3798 6511
Email: j-jasper@ax.jp.nec.com
MC Services AG
Katja Arnold, Laurie Doyle
Phone: +49 89 210228 0
Email: vaximm@mc-services.eu
